Objective Bile acids are important regulators of intestinal physiology, and the nuclear bile acid receptor, farnesoid X receptor (FXR), is emerging as a promising therapeutic target for several ...
A study demonstrated that pharmacological activation of the farnesoid X receptor (FXR) in a mouse model could prevent PNAC by restoring liver function and reducing inflammation. This suggests that ...
The Swiss pharma said it is to begin a phase IIb trial of one of its Farnesoid X receptor (FXR) agonists in combination with Allergan’s cenicriviroc in NASH. A group of around half a dozen ...
Results Serum concentrations of primary and secondary bile acids were increased in patients with NAFLD. In per cent, the farnesoid X receptor (FXR) antagonistic DCA was increased, while the agonistic ...
Results: It was found that HDCA treatment of CRC cells was able to significantly inhibit the proliferative capacity of the cells. Furthermore, it was discovered that HDCA primarily stimulated ...
Charu V, Liang JW, Mannalithara A, Kwong A, Tian, Lu, and Kim, WR. Benchmarking clinical risk prediction algorithms with ensemble machine learning: An illustration of the superlearner algorithm for ...
Dr. Patterson is the Tombros Early Career Professor, Professor of Molecular Toxicology, and Professor of Biochemistry and Molecular Biology at the Pennsylvania State University, University Park, PA ...
Obeticholic acid (OCA): For patients unresponsive to UDCA, OCA, a farnesoid X receptor (FXR) agonist, has shown efficacy in improving biochemical responses and delaying disease progression.
Obeticholic acid, an agonist of the farnesoid X receptor and the first drug to have supportive phase 3 histological data for fibrotic NASH, was refused FDA approval on the basis of modest treatment ...
In many ways, that relationship revolves around a specific protein called the farnesoid X receptor, or FXR, which helps maintain a healthy gut through its intimate relationship with bile acids.